Skip to main content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Vitamin D and tuberculosis: a multicenter study in children

  • 1,
  • 1,
  • 2,
  • 3,
  • 1,
  • 1Email author and
  • 1
BMC Infectious Diseases201414:652

https://doi.org/10.1186/s12879-014-0652-7

©  Venturini et al.; licensee BioMed Central Ltd. 2014

  • Received: 1 June 2014
  • Accepted: 21 November 2014
  • Published:
Open Peer Review reports

Abstract

Background

The aim of this study is to evaluate vitamin D levels in children with latent and active TB compared to healthy controls of the same age and ethnical background.

Methods

A multicenter observational study has been conducted in three tertiary care paediatric centres: Anna Meyer Children's University Hospital, Florence, Italy; Evelina London Children's Hospital, London, United Kingdom and Great Ormond Street Hospital, London, United Kingdom. Vitamin D was considered deficient if the serum level was <25 nmol/L, insufficient between 25 and 50 nmol/L and sufficient for a level >50 nmol/L.

Results

The study population included 996 children screened for TB, which have been tested for vitamin D. Forty-four children (4.4%) had active TB, 138 (13.9%) latent TB and 814 (81.7%) were controls. Our study confirmed a high prevalence of hypovitaminosis D in the study population. A multivariate analysis confirmed an increased risk of hypovitaminosis D in children with latent and active TB compared to controls [(P = 0.018; RR = 1.61; 95% CI: 1.086-2.388), (P < 0.0001; RR = 4.587; 95% CI:1.190-9.608)].

Conclusions

Hypovitaminosis D was significantly associated with TB infection in our study. Further studies are needed to evaluate a possible role of vitamin D in the treatment and prevention of tuberculosis in children.

Keywords

  • Vitamin D
  • Tuberculosis
  • Children

Background

In the pre-antibiotic era, cod liver oil and sunlight exposure were used to treat tuberculosis (TB) [1],[2]. More recently, increasing evidences from in vitro studies suggest that vitamin D enhances antimycobacterial immunity [3]. Several authors reported hypovitaminosis D in TB patients [4]–[6], and serum level of vitamin D [25-hydroxycholecalciferol) was found to be lower in TB patients than in healthy controls [7]–[14]. A recent study conducted among adult TB contacts found that 94% of recruits were vitamin D insufficient and that a single, oral 2.5 mg dose of vitamin D significantly enhanced their anti-mycobacterial immunity in vitro [7]. Factors such as low socioeconomic status, poor nutrition, traditional/cultural traits, and little exposure to sunlight may contribute to vitamin D deficiency [15].

Mechanisms through which vitamin D modulates the immune system in the response to Mycobacterium tuberculosis infection are not completely understood, two possible mechanisms have emerged as the most likely. Vitamin D appears to reduce the viability of M. tuberculosis by enhancing the fusion of the phagosome and lysosome in infected macrophages [16]. In addition, vitamin D may enhance the production of LL-37, an antimicrobial peptide of the cathelicidin family [16]–[19]. Antimicrobial peptides, such as defensin and cathelicidin, are involved as a first line of defences in the prevention of infections, including tuberculosis. The presence of vitamin D in neutrophils and macrophages up-regulates in a dose-dependent manner the hCAP-18 gene that codes for LL-37, which suggests that vitamin D induction of LL-37 may play a role in host defences against TB infection [3],[16].

Vitamin D exerts its actions through vitamin D receptor (VDR), a nuclear hormone receptor. Polymorphisms in the VDR gene, which may influence VDR activity and subsequent downstream vitamin D mediated effects, were therefore studied as potential candidates of risk markers for various clinical outcomes [20],[21].

Clinical trials [8],[10],[22]–[24] have been conducted to test whether vitamin D therapy improves TB outcomes, suggesting that vitamin D may be beneficial as an adjunctive treatment to the traditional therapy in patients with TB; however, additional trials in children need to be conducted to clarify its role [25].

Methods

A multicenter study was conducted in three tertiary care paediatric centres: Anna Meyer Children's University Hospital, Florence, Italy; Evelina London Children's Hospital, London, United Kingdom and Great Ormond Street Hospital, London, United Kingdom. The data regarding the period of time between July 2008 and January 2013 were collected retrospectively, whereas those between February and September 2013 prospectively. Written informed consent for participation in the study was obtained from children's parent or guardian. The aim of the study was to evaluate vitamin D levels in children with latent and active tuberculosis, compared to healthy controls of the same age and ethnical background. Secondary objective was to evaluate potential differences between groups of patients (considering age, race, enrolling centre, vitamin D supplementation, latent or active tuberculosis).

Study design

Children (aged <18 years) investigated for TB infection between July 2008 and September 2013, for whom vitamin D was tested during the first visit, were eligible. The reasons for referral to the paediatric infectious diseases centres were clinical suspicious or confirmed TB disease, history of TB contact or immigrated/adopted child from a TB endemic country within the previous 2 years. Children with congenital or acquired immunodeficiency were excluded.

For each child the following data were entered into the study database: name, age, gender, ethnic group, familial and personal history including risk factors for TB infection and for vitamin D deficiency, bacillus Camette-Guerin (BCG) vaccination and physical examination. Data about tests performed were also included, in particular vitamin D level (25-hydroxycholecalciferol, 25-OHD), tuberculin skin test (TST), interferon-γ release assay (IGRA), and if available calcium, phosphate, chest x-ray, chest computerised tomography, gastric aspirate or sputum (microscopy, culture and polymerase chain reaction for M. tuberculosis) and anti-tubercular treatment. All results were recorded in the study database following the international standards for the protection of privacy and personal information.

Ethical issues

This study was approved by the Ethical Committees of the hospitals involved: Anna Meyer Children's University Hospital, Florence, Italy; Evelina London Children's Hospital, London, United Kingdom and Great Ormond Street Hospital, London, United Kingdom.

Case definitions

TB disease

Active TB diagnosis was assigned to any child with Mycobacterium tuberculosis cultured or detected by microscopy or molecular methods from sputum, gastric aspirate or other biologic samples. Active TB diagnosis was also assigned to any child with clinical and radiological evidence of TB disease, and with either a history of exposure to an infectious case or a positive TST. In the absence of a recognized gold standard, latent tuberculosis diagnosis was assigned to any child with a positive TST and/or IGRA and no clinical, bacteriological or radiographic evidence of active TB [26]. In the absence of those criteria children were included in the control group.

Hypovitaminosis D

Vitamin D level was evaluated testing for 25-OHD, which is considered its best indicator [27]. Following the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) definition, 25-OHD was considered deficient in case of a serum vitamin D level less than 25 nmol/L, insufficient between 25 and 50 nmol/L and sufficient for level above 50 nmol/L [28].

Statistical analysis

Continuous measurements analyzed were: age (years), weight (kilograms), height (centimetres), 25-OHD serum level (nmol/L), calcium and phosphate levels (mmol/L). Median and interquartile range (IQR) were calculated for those variables in the study groups. Categorical data were compared using the Chi-squared test (or Fisher's exact test, when expected cell sizes were smaller than five). The Wilcoxon-Mann–Whitney test was used for continuous measurements to test relationships in unpaired analysis, when assumed that the dependent variable was a not normally distributed interval variable. Moreover, the risk factors for vitamin D deficiency were evaluated using univariate and multivariate logistic regression. The variables included in the analysis were: TB infection status (active TB, latent TB, and control), gender, age, ethnicity at risk for vitamin D deficiency, immigration, seasonality (categorized ad autumn-winter and spring-summer). For each factor the relative risk (RR) and 95% confident intervals (95% CI) were evaluated. Statistical analysis was performed using the statistical software SPSS for Windows, version 12.0. P <0.05 was considered statistically significant.

Results

Population

Nine hundred and ninety-six children were included in this study: 15 (1.5%) from Great Ormond Street Hospital, London, UK; 63 (6.4%) from Evelina London Children’s Hospital, London, UK; and 918 (92.1%) from Anna Meyer Children's University Hospital, Florence, Italy. The study population characteristics are summarized in Table 1.
Table 1

Study population characteristics

 

Controls n = 814

Latent TB n = 138

Active TB n = 44

Total n = 996

P

Enrolling centre, n (%):

    

<0.0001

- Evelina London Children’s

21 (2.6%)

25 (18.1%)

17 (38.6%)

63 (6.4%)

 

Hospital, London, UK

     

- Great Ormond Street

0 (0%)

0 (0%)

15 (34.1%)

15 (1.5%)

 

Hospital, London, UK

     

- Anna Meyer Children's University Hospital, Florence, Italy

793 (97.4%)

113 (81.9%)

12 (27.3 %)

918 (92.1%)

 

Age in years, median (IQR)

5.5 (3.1-8.1)

6.9 (4.3-10.8)

4.7 (3.0-11.6)

5.8 (3.1-8.5)

<0.0001

Gender, n (%):

    

<0.0001

- Male

496 (60.9%)

85 (61.6%)

15 (34.1%)

596 (59.4%)

 

- Female

310 (38.1 %)

52 (37.7%)

29 (65.9 %)

391 (39.6%)

 

- Not known

8 (1%)

1 (0.7%)

0 (0%)

9 (0.9%)

 

Country of origin * , n (%):

    

<0.0001

- Asia

146 (17.9%)

19 (13.8%)

4 (9.1%)

169 (17%)

 

- Latin America

183 (22.5%)

24 (17.4%)

4 (9.1%)

211 (21.2%)

 

- Eastern Europe§

269 (33%)

57 (41.3%)

5 (11.4%)

331 (33.2%)

 

- Western Europe

36 (4.4%)

7 (5.1%)

3 (6.8 %)

46 (4.6%)

 

- Nord Africa

16 (2%)

1 (0.7%)

2 (4.5%)

19 (1.9%)

 

- Sub-Saharan Africa

151 (18.6%)

29 (21%)

25 (56.8 %)

205 (20.6%)

 

- Other

8 (1%)

0 (0%)

0 (0%)

8 (0.8%)

 

- Not known

5 (0.6%)

1 (0.7%)

1 (2.3%)

7 (0.7%)

 

Ethnic group, n (%):

    

<0.0001

- African

168 (20.7%)

30 (21.7%)

27 (61.4%)

225 (22.6%)

 

- Asiatic

146 (17.9%)

19 (13.8%)

4 (9.1%)

169 (17%)

 

- Caucasian

306 (37.6%)

64 (46.4%)

8 (18.2%)

378 (37.9%)

 

- Hispanic

183 (22.5%)

24 (17.4%)

4 (9.1%)

211 (21.2%)

 

- Other

6 (0.7%)

0 (0%)

0 (0%)

6 (0.6%)

 

- Not known

5 (0.6%)

1 (0.7%)

1 (2.2%)

7 (0.7%)

 

BCG, n (%):

    

0.109

- Yes

460 (56.5%)

89 (64.5%)

20 (45.5%)

569 (57.1%)

 

- No

244 (30.0%)

40 (29.0%)

19 (43.2%)

303 (30.4%)

 

- Not known

110 (13.5%)

9 (6.5%)

5 (11.4%)

124 (12.4%)

 

Risk factors for vitamin D

    

0.932

deficiency†, n (%):

     

- Yes

470 (57.7%)

74 (53.6%)

32 (72.7%)

576 (57.8%)

 

- No

344 (42.3%)

64 (46.4%)

12 (27.3%)

420 (42.2%)

 

Risk factors for TB

    

<0.0001

infection, n (%):

     

- Tb contact

92 (11.4%)

31 (22.5%)

27 (21.2%)

150 (15.1%)

 

- Travel to/immigrated from

695 (85.3%)

104 (75.4%)

10 (22.8%)

809 (80.1%)

 

TB endemic country

     

- Not known

27 (3.3%)

3 (2.1%)

7 (15.9%)

37 (3.7%)

 

IGRA, n (%):

    

<0.0001

- Positive

0 (0.0%)

45 (32.6%)

28 (63.6%)

73 (7.3%)

 

- Negative

792 (97.3%)

71 (51.4%)

7 (15.9%)

870 (87.3%)

 

- Not known

22 (2.7%)

22 (15.9%)

9 (20.5%)

53 (5.3%)

 

TST, n (%):

    

<0.0001

- Positive

0 (0.0%)

120 (87%)

32 (72.7%)

152 (15.3%)

 

- Negative

777 (95.5%)

10 (7.2%)

2 (4.5%)

789 (79.2%)

 

- Not known

37 (4.5%)

8 (5.8%)

10 (22.7%)

55 (55.2%)

 

*Whether the child’s family is originally from a TB endemic country, this has been indicated as country of origin, independently from the country of birth.

§Albania, Belarus, Bulgaria, Kosovo, Macedonia, Moldavia, Poland, Czech Republic, Romania, Russia, Serbia, Slovakia, Slovenia, Ukraine, Hungary.

†African, Asiatic and Hispanic ethnic group.

TB status

Forty-four (4.4%) children met the criteria for active TB. The most common condition was pulmonary TB (n = 24; 54.5%). Extra-pulmonary TB was in order of frequency: lymphadenitis (n = 5; 11.4%), pleural-peritoneal (n = 4; 9.1%), skeletal (n = 4; 9.1%), ocular (n = 1; 2.3%), meningeal (n = 1; 2.3%). Miliary TB was found in 5 patients (11.4%). The median length of the treatment was 7 months (range 6–12). Quadruple therapy (isoniazid, rifampicin, ethambutol, pyrazinamide) was used in 36 children, in 4 of those in association with steroids. In other 8 cases different anti-TB treatment associations have been used, mostly because of resistant mycobacteria.

One hundred and thirty-eight (13.9%) children met the criteria for latent TB. Double therapy (isoniazid and rifampicin) for 3 months was the commonest combination used (91.3%, n = 126). The controls enrolled in the study were 814 (81.7%).

Vitamin D, calcium and phosphate levels in the study groups

Vitamin D levels in the different study groups are reported in Table 2 and illustrated in Figure 1. About half (467; 46.9%) of the children tested, independently from the TB status, resulted to have an insufficient or deficient vitamin D level. Hypovitaminosis D was found respectively in 354 (43.5%) of controls, 80 (58%) latent TB and 33 (75%) active TB. The statistical analysis with the Mann–Whitney U test showed that vitamin D level was significantly lower in case of latent and active TB compared to controls (p < 0.0001), with median level respectively of 45 nmol/L (IQR: 30–62.5), 27.8 nmol/L (IQR: 19–50) and 52.5 nmol/L (IQR: 31.5-67.5).
Table 2

Vitamin D, calcium and phosphate levels in the different study groups

 

Controls n = 814

Latent TB n = 138

Active TB n = 44

Total n = 996

P

Vitamin D level, n (%):

    

0.0001

- Deficient (<25 nmol/L)

113 (13.9%)

28 (20.3%)

18 (40.9%)

159 (16%)

 

- Insufficient (25–50 noml/L)

241 (29.6%)

52 (37.7%)

15 (34.1%)

308 (30.9%)

 

- Sufficient (>50 nmol/L)

460 (56.5%)

58 (42%)

11 (25%)

529 (53.1%)

 

Vitamin D level (nmol/L), median (IQR)

52.5 (31.5-67.5)

45 (30–62.5)

27.8 (19–50)

35 (24–54.5)

0.0001

Calcium (mmol/L), median (IQR)

2.38 (2.3-2.45)

2.38 (2.3-2.42)

2.35 (2.25-2.45)

2.4 (2.26-2.46)

0.709

Phosphate (mmol/L), median (IQR)

1.62 (1.49-1.71)

1.75 (1.32-1.78)

1.42 (1.23-1.6)

1.5 (1.28-1.61)

0.002

Figure 1
Figure 1

Vitamin D levels (median and IQR) in the different study groups. About half (467; 46.9%) of the children tested, independently from the TB status, resulted to have an insufficient or deficient vitamin D level. Hypovitaminosis D was found respectively in 354 (43.5%) of controls, 80 (58%) latent TB and 33 (75%) active TB.

Vitamin D levels were significantly lower in latent TB compared to controls (p = 0.002), in active TB compared to controls (p < 0.0001) and in active TB compared to latent TB (p = 0.001).

Moreover, a deficient vitamin D level was found in higher percentage in the active TB group (n = 18; 40.9%) compared to latent TB (n = 28; 20.3%) and controls (13.9%) (P < 0.0001). An insufficient level of vitamin D was more frequently found in the latent TB group (n = 113; 37.7%, P < 0.0001) (Figure 2).
Figure 2
Figure 2

Vitamin D status defined by ESPGHAN according to TB status. A deficient vitamin D level was found in higher percentage in the active TB group (n = 18; 40.9%) compared to latent TB (n = 28; 20.3%) and controls (13.9%) (P < 0.0001). An insufficient level of vitamin D was more frequently found in the latent TB group (n = 113; 37.7%, P < 0.0001).

All the variable analysed were statistically significant also according to the US Endocrinology Society vitamin D status classification (P < 0.0001) (29).

Calcium and phosphate levels (median and IQR) in the different study groups are reported in Table 2.

In the study population 159 (16%) children were vitamin D deficient, 308 (30.9%) insufficient and 529 (53.1%) sufficient.

The correlation between vitamin D status and other factors (age, gender, seasonality, calcium and phosphate levels) has been reported in Table 3.
Table 3

Characteristics of the population according to vitamin D status

 

Deficient n = 159

Insufficient n = 308

Sufficient n = 529

Total n = 996

P

TB status, n (%):

    

<0.0001

- Controls

113 (71.1%)

241 (78.2%)

460 (87%)

814 (81.7%)

 

- Latent TB

28 (17.6%)

52 (16.9%)

58 (11%)

138 (13.9%)

 

- Active TB

18 (11.3%)

15 (4.9%)

11 (2%)

44 (4.4%)

 

Enrolling centre, n (%):

    

<0.0001

- Evelina London Children’s

26 (16.4%)

23 (7.5%)

14 (2.6%)

63 (6.4%)

 

Hospital, London, UK

     

- Great Ormond Street

8 (5%)

5 (1.6%)

2 (0.4%)

15 (1.5%)

 

Hospital, London, UK

     

- Anna Meyer Children's University Hospital, Florence, Italy

125 (78.6%)

280 (90.9%)

513 (97%)

918 (92.1%)

 

Age, median (IQR)

6.5 (4.2-10.3)

6.6 (4–9.7)

4.8 (2.5-7.6)

5.8 (3.1-8.5)

<0.0001

Gender, n (%):

    

0.106

- Male

85 (53.5%)

182 (59.1%)

329 (62.2%)

596 (59.8%)

 

- Female

74 (46.5%)

122 (39.6%)

195 (36.9%)

391 (39.3%)

 

- Not known

0 (0%)

4 (1.3%)

5 (0.9%)

9 (0.9%)

 

Country of origin*, n (%):

    

<0.0001

- Asia

27 (17%)

44 (14.3%)

98 (18.5%)

169 (17%)

 

- Latin America

25 (15.7%)

74 (24%)

112 (21.2%)

211 (21.2%)

 

- Eastern Europe §

48 (30.2%)

95 (30.8%)

188 (35.5%)

331 (33.2%)

 

- Western Europe

4 (2.5%)

18 (5.8%)

24 (4.5%)

46 (4.6%)

 

- Nord Africa

7 (4.4%)

8 (2.6%)

4 (0.8%)

19 (1.9%)

 

- Sub-Saharan Africa

42 (26.4%)

65 (21.1%)

98 (18.5%)

205 (20.6%)

 

- Other

1 (0.6%)

3 (1%)

4 (0.8%)

8 (0.8%)

 

- Not known

5 (3.1%)

1 (0.3%)

1 (0.2%)

7 (0.7%)

 

Ethnic group, n (%):

    

<0.0001

- African

50 (30.8%)

74 (24%)

101 (19.1%)

225 (22.6%)

 

- Asiatic

24 (15.1%)

43 (14%)

102 (19.3%)

169 (17%)

 

- Caucasian

52 (32.7%)

115 (37.3%)

211 (39.9%)

378 (37.9%)

 

- Hispanic

27 (17%)

73 (23.7%)

111 (21%)

211 (21.2%)

 

- Other

1 (1.2%)

2 (0.7%)

3 (0.5%)

6 (0.6%)

 

- Not known

5 (3.2%)

1 (0.3%)

1 (0.2%)

7 (0.7%)

 

Risk factors for vitamin D

    

0.932

deficiency†, n (%):

     

- Yes

93 (58.5%)

180 (58.4%)

303 (57.3%)

576 (57.8%)

 

- No

66 (41.5%)

128 (41.6%)

226 (42.7%)

420 (42.2%)

 

Season when blood test was

    

<0.0001

done, n (%):

     

- Spring-Summer

58 (36.5%)

145 (47.1)

339 (64.1%)

542 (54.4%)

 

- Winter-Autumn

101 (63.5%)

163 (52.9)

190 (35.9%)

454 (45.6%)

 

Vitamin D level (nmol/L), median (IQR)

20 (15.5-22.5)

37.5 (32.5-42.5)

72.5 (57.5-87.5)

35 (24–54.5)

 

Calcium (mmol/L), median (IQR)

2.35 (2.28-2.42)

2.37 (2.3-2.43)

2.38 (2.33-2.48)

2.4 (2.26-2.46)

0.030

Phosphate (mmol/L), median (IQR)

1.5 (1.3-1.65)

1.59 (1.41-1.68)

1.65 (1.49-1.81)

1.5 (1.28-1.61)

0.001

*Whether the child’s family is originally from a TB endemic country, this has been indicated as country of origin, independently from the country of birth.

§Albania, Belarus, Bulgaria, Kosovo, Macedonia, Moldavia, Poland, Czech Republic, Romania, Russia, Serbia, Slovakia, Slovenia, Ukraine, Hungary.

†African, Asiatic and Hispanic ethnic group.

Vitamin D level was significantly lower if tested during Autumn-Winter compared to Spring-Summer (P < 0.0001) (Figure 3).
Figure 3
Figure 3

Vitamin D level according to seasonality. Vitamin D level was significantly lower if tested during Autumn-Winter compared to Spring-Summer (P < 0.0001).

Multivariate analysis

A multivariate logistic regression analysis was used to exclude possible confounding factors. This analysis confirmed the risk of vitamin D deficiency to be statistically correlated with TB infection (RR = 1.61; 95% CI:1.086-2.388; P = 0.018;), and higher in active TB compared to latent TB and controls, ( RR = 4.587; 95% CI: 1.190-9.608; P < 0.0001). In the multivariate analysis the results were adjusted for the different centres.

There was no significant correlation between hypovitaminosis D and gender (P = 0.113; RR = 0.799; 95% CI: 0.605-1.055), ethnicity at risk of hypovitaminosis D (P = 0.688; RR = 1.610; 95% CI: 0.715-1.747) and immigration (P = 0.428; RR = 1.316; 95% CI: 0.668-2.590). On the contrary, a correlation between hypovitaminosis D and age (P < 0.0001; RR = 1.147; 95% CI: 1.105-1.190) and between vitamin D deficiency and seasonality (P < 0.0001; RR = 2.208; 95% CI: 2.132-3.698) was found.

Vitamin D supplementation

In case of hypovitaminosis D, different vitamin D supplementation protocols were used in the three centres, according with the most recent international guidelines [28]–[31]. At Anna Meyer Children's University Hospital, Florence, Italy, 1000 IU of colecalciferol were administered daily for 8 weeks. At Evelina London Children’s Hospital, London, UK, 3,000, 6,000, 10,000 or 20,000 IU of colecalciferol were used daily for 6 weeks depending on the severity of hypovitaminosis D. At Great Ormond Street Hospital, London, UK 50,000 IU of ergocalciferol were administered daily for 3 to 6 days.

Only one-third (133; 28.5%) of the patients with a low level of vitamin D received vitamin D supplementation. Vitamin D supplementation was prescribed in 71 controls, 36 latent TB and 26 active TB, respectively 20%, 45% and 79% of children with hypovitaminosis D in the 3 different groups.

Discussion

The high prevalence of hypovitaminosis D in children [32],[33] is confirmed in our study, based on a large data set, reaching 47% of children tested, independently from their TB status.

The correlation between vitamin D deficiency and TB disease was previously demonstrated in adults [4]–[6],[8]–[14], although some authors do not agree with this hypothesis [34]–[40]. No paediatric study with a matched control group is available in literature, and our study’s aim is to fill this gap. Three studies on a possible correlation between vitamin D deficiency and TB in the paediatric population were previously published [41]–[43], including overall 442 children. In the first study on refugee children, a vitamin D level was significantly lower in 92 children with TB infection compared to 236 healthy controls [41]. The main limitations of this retrospective study were the omission of routine IGRA testing in the definition of TB status and the missing data about BCG vaccination [41]. Hypovitaminosis D prevalence in latent and active TB was 86% in a retrospective study on 64 children [42]. The principal limitation of this study was the lack of an age and ethnically matched control group without a history of TB infection or disease [42]. Finally, in a randomised study, done on a small number of children (n = 24), vitamin D supplementation (colecalciferol 1000 UI daily for 8 weeks) was added to TB treatment, leading to clinical and radiological improvement compared to the standard treatment alone [43].

The correlation between low vitamin D and TB disease is confirmed in our study on a large paediatric population including a matched control group. Hypovitaminosis D affected up to 75% children with active TB (P < 0.0001). Moreover, the active TB group exhibited the lowest level of vitamin D. Hypovitaminosis D was four times more likely in children with active TB compared to healthy controls. This correlation was confirmed using a multivariate logistic regression analysis, in order to exclude possible confounding factors, and the results were adjusted considering also the different enrolling centre.

About two-third of the study population ethnicity was at high risk for vitamin D deficiency (African, Asiatic and Hispanic). It is well known that the major risk factors in these populations are dark skin, reduced exposure to sunlight due to long clothing and vegetarian diet [32]. The ethnical background at risk of hypovitaminosis D were homogeneously distributed in the 3 study groups. Interestingly, in our study hypovitaminosis D occurred also in the Caucasian group, accounting for about one-third of the cases. Vitamin D was deficient in 32.7% of Caucasian children and insufficient in 37.3%. Moreover, about 80% of children tested in the UK had hypovitaminosis D (respectively 43.6% was vitamin D deficient and 35.9% insufficient) compared to 44.1% of children tested in Italy (respectively 13.6% was vitamin D deficient and 30.5% insufficient). This difference could be mainly explained by lower sun exposure in UK with respect to Italy and probably also by different diet within the two countries. However, the high percentage of hypovitaminosis in Italy despite good sun exposure, affecting about half of the children tested, should increase the awareness of this problem also in countries known to be at low risk for vitamin D deficiency.

Hypovitaminosis D was statistically more frequent if tested during autumn and winter compared to spring and summer. This seasonality has been well described and is mainly related to sun exposure [6],[12],[41],[44].

Surprisingly, only one-third of the patients with hypovitaminosis D received vitamin D supplementation, with different protocols depending on the prescribing centre. The protocols used in the three centres were in agreement with the most recent international guidelines [28]–[31]. This data should alert the physicians about the need of vitamin D supplementation in children with hypovitaminosis, to prevent rickets and its complications. However no clinical sign of rickets was reported in our study population. The choice of vitamin D regimen in the paediatric population should take count of compliance, especially in young children and in TB patients, which already receive a significant amount of drugs. The need of clear guidelines for children with hypovitaminosis D in this setting should be addressed, in order to unify the management of vitamin D supplementation in this group of patients.

The major limitations of our study are: the lack of homogeneity between the study groups, as the majority of controls were enrolled in the Italian centre. To minimize the influence of this factor on our results a multivariate analysis was performed, including the enrolling centre as a categorical variable. Moreover data regarding parathyroid hormone, alkaline phosphatase were lacking. In our study the hypovitaminosis D definition used was in keeping with ESPGHAN guidelines [28], although we were aware about different definitions. To avoid this bias we performed the analysis considering also vitamin D status classification by the US Endocrine Society [29], and the results didn’t change substantially.

Conclusions

Our large population study confirms an increasing incidence of hypovitaminosis D in Europe, within native and immigrated children, and the role played by vitamin D status in TB disease.

In our study hypovitaminosis D was significantly associated with TB infection. Further studies are needed to evaluate a possible role of vitamin D in the treatment and prevention of tuberculosis in children, especially novel randomized controlled trials to compare TB treatment outcomes in children receiving vitamin D supplementation in addition to the standard therapy.

Abbreviations

25-OHD: 

25-Hydroxycholecalciferol

BCG: 

Bacillus Calmette-Guerin

CI: 

Confidence intervals

ESPGHAN: 

European Society for Paediatric Gastroenterology, Hepatology and Nutrition

IGRA: 

Interferon-γ release assay

IQR: 

Interquartile range

RR: 

Relative risk

TB: 

Tuberculosis

TST: 

Tuberculin skin test

VDR: 

Vitamin D receptor

Declarations

Authors’ Affiliations

(1)
Department of Health Sciences, University of Florence, Anna Meyer Children’s University Hospital, viale Pieraccini 24, Florence, I-50139, Italy
(2)
Evelina London Children’s Hospital, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
(3)
Department of Infectious Diseases, Great Ormond Street Hospital for Children NHS Trust, Great Ormond Street, London, WC1N 3JH, UK

References

  1. Roelandts R: The history of phototherapy: something new under the sun?. J Am Acad Dermatol. 2002, 46: 926-930. 10.1067/mjd.2002.121354.View ArticlePubMedGoogle Scholar
  2. Grad R: Cod and the consumptive: a brief history of cod-liver oil in the treatment of pulmonary tuberculosis. Pharm Hist. 2004, 46: 106-120.PubMedGoogle Scholar
  3. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zügel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL: Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006, 311: 1770-1773. 10.1126/science.1123933.View ArticlePubMedGoogle Scholar
  4. Talat N, Perry S, Parsonnet J, Dawood G, Hussain R: Vitamin D deficiency and tuberculosis progression. Emerg Infect Dis. 2010, 16: 853-855. 10.3201/eid1605.091693.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP, Packe GE, Moore-Gillon JC, Darmalingam M, Davidson RN, Milburn HJ, Baker LV, Barker RD, Woodward NJ, Venton TR, Barnes KE, Mullett CJ, Coussens AK, Rutterford CM, Mein CA, Davies GR, Wilkinson RJ, Nikolayevskyy V, Drobniewski FA, Eldridge SM, Griffiths CJ: High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet. 2011, 377: 242-250. 10.1016/S0140-6736(10)61889-2.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Martineau AR, Nhamoyebonde S, Oni T, Rangaka MX, Marais S, Bangani N, Tsekela R, Bashe L, de Azevedo V, Caldwell J, Venton TR, Timms PM, Wilkinson KA, Wilkinson RJ: Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc Natl Acad Sci U S A. 2011, 108: 19013-19017. 10.1073/pnas.1111825108.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Martineau AR, Wilkinson RJ, Wilkinson KA, Newton SM, Kampmann B, Hall BM, Packe GE, Davidson RN, Eldridge SM, Maunsell ZJ, Rainbow SJ, Berry JL, Griffiths CJ: A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med. 2007, 176: 208-213. 10.1164/rccm.200701-007OC.View ArticlePubMedGoogle Scholar
  8. Davies PD, Brown RC, Woodhead JS: Serum concentrations of vitamin D metabolites in untreated tuberculosis. Thorax. 1985, 40: 187-190. 10.1136/thx.40.3.187.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Davies PD, Church HA, Brown RC, Woodhead JS: Raised serum calcium in tuberculosis patients in Africa. Eur J Respir Dis. 1987, 71: 341-344.PubMedGoogle Scholar
  10. Wilkinson RJ, Llewelyn M, Toossi Z, Patel P, Pasvol G, Lalvani A, Wright D, Latif M, Davidson RN: Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case–control study. Lancet. 2000, 355: 618-621. 10.1016/S0140-6736(99)02301-6.View ArticlePubMedGoogle Scholar
  11. Sasidharan PK, Rajeev E, Vijayakumari V: Tuberculosis and vitamin D deficiency. J Assoc Physicians India. 2002, 50: 554-558.PubMedGoogle Scholar
  12. Sita-Lumsden A, Lapthorn G, Swaminathan R, Milburn HJ: Reactivation of tuberculosis and vitamin D deficiency: the contribution of diet and exposure to sunlight. Thorax. 2007, 62: 1003-1007. 10.1136/thx.2006.070060.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Gibney KB, MacGregor L, Leder K: Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa. Clin Infect Dis. 2008, 46: 443-446. 10.1086/525268.View ArticlePubMedGoogle Scholar
  14. Friis H, Range N, Pedersen ML, Mølgaard C, Changalucha J, Krarup H, Magnussen P, Søborg C, Andersen AB: Hypovitaminosis D is common among pulmonary tuberculosis patients in Tanzania but is not explained by the acute phase response. J Nutr. 2008, 138: 2474-2480. 10.3945/jn.108.094979.View ArticlePubMedGoogle Scholar
  15. Nnoaham KE, Clarke A: Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int J Epidemiol. 2008, 37: 113-119. 10.1093/ije/dym247.View ArticlePubMedGoogle Scholar
  16. Chocano-Bedoya P, Ronnenberg AG: Vitamin D and tuberculosis. Nutr Rev. 2009, 67: 289-293. 10.1111/j.1753-4887.2009.00195.x.View ArticlePubMedGoogle Scholar
  17. Martineau AR, Wilkinson KA, Newton SM, Floto RA, Norman AW, Skolimowska K, Davidson RN, Sørensen OE, Kampmann B, Griffiths CJ, Wilkinson RJ: IFN-gamma- and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J Immunol. 2007, 178: 7190-7198. 10.4049/jimmunol.178.11.7190.View ArticlePubMedGoogle Scholar
  18. Ralph AP, Kelly PM, Anstey NM: L-arginine and vitamin D: novel adjunctive immunotherapies in tuberculosis. Trends Microbiol. 2008, 16: 336-344. 10.1016/j.tim.2008.04.003.View ArticlePubMedGoogle Scholar
  19. Campbell GR, Spector SA: Vitamin D inhibits human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection in macrophages through the induction of autophagy. PLoS Pathog. 2012, 8: 1523-1525.Google Scholar
  20. Valdivielso JM, Fernandez E: Vitamin D receptor polymorphisms and diseases. Clin Chim Acta. 2006, 371: 1-12. 10.1016/j.cca.2006.02.016.View ArticlePubMedGoogle Scholar
  21. Gao L, Tao Y, Zhang L, Jin Q: Vitamin D receptor genetic polymorphisms and tuberculosis: update systematic review and meta-analysis. Int J Tuberc Lung Dis. 2010, 14: 15-23.PubMedGoogle Scholar
  22. Martineau AR, Honecker FU, Wilkinson RJ, Griffiths CJ: Vitamin D in the treatment of pulmonary tuberculosis. J Steroid Biochem Mol Biol. 2007, 103: 793-798. 10.1016/j.jsbmb.2006.12.052.View ArticlePubMedGoogle Scholar
  23. Nursyam EW, Amin Z, Rumende CM: The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med Indones. 2006, 38: 3-5.PubMedGoogle Scholar
  24. Wejse C, Gomes VF, Rabna P, Gustafson P, Aaby P, Lisse IM, Andersen PL, Glerup H, Sodemann M: Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2009, 179: 843-850. 10.1164/rccm.200804-567OC.View ArticlePubMedGoogle Scholar
  25. Sinclair D, Abba K, Grobler L, Sudarsanam TD: Nutritional supplements for people being treated for active tuberculosis. Cochrane Database Syst Rev. 2011, 11:Google Scholar
  26. American Academy of Pediatrics: Tuberculosis. Red Book: 2012 Report of the Committee on Infectious Diseases. Edited by: Pickering LK, Baker CJ, Kimberlin DW, Long SS. 2012, American Academy of Pediatrics, Elk Grove Village, IL, 680-701.Google Scholar
  27. Bikle D: Nonclassic actions of vitamin D. J Clin Endocrinol Metab. 2009, 94: 26-34. 10.1210/jc.2008-1454.View ArticlePubMedGoogle Scholar
  28. Braegger C, Campoy C, Colomb V, Decsi T, Domellof M, Fewtrell M, Hojsak I, Mihatsch W, Molgaard C, Shamir R, Turck D, van Goudoever J, ESPGHAN Committee on Nutrition: Vitamin D in the Healthy Paediatric Population: A Position Paper by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr. 2013, 56: 692-701. 10.1097/MPG.0b013e31828f3c05.View ArticlePubMedGoogle Scholar
  29. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine Society: Evaluation, Treatment, and Prevention of Vitamin D Deficiency: An Endocrine Society Clinical Practice Guideline. 2011,Google Scholar
  30. Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M: Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics. 2008, 122 (3): 98-417.Google Scholar
  31. Hochberg Z, Bereket A, Davenport M, de Waal HA D-V, De Schepper J, Levine MA, European Society for Paediatric Endocrinology (ESPE) Bone Club: Consensus development for the supplementation of vitamin D in childhood and adolescence. Horm Res. 2002, 58: 39-51. 10.1159/000063214.View ArticlePubMedGoogle Scholar
  32. Braegger C, Campoy C, Colomb V, Decsi T, Domellof M, Fewtrell M, ESPGHAN Committee on Nutrition: Vitamin D in the healthy European paediatric population. J Pediatr Gastroenterol Nutr. 2013, 56: 692-701. 10.1097/MPG.0b013e31828f3c05.View ArticlePubMedGoogle Scholar
  33. Holick MF, Chen TC: Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr. 2008, 87: 1080-1086.Google Scholar
  34. Grange JM, Davies PD, Brown RC, Woodhead JS, Kardjito T: A study of vitamin D levels in Indonesian patients with untreated pulmonary tuberculosis. Tubercle. 1985, 66: 187-191. 10.1016/0041-3879(85)90035-2.View ArticlePubMedGoogle Scholar
  35. Chan TY: Osteomalacia during rifampicin and isoniazid therapy is rare in Hong Kong. Int J Clin Pharmacol Ther. 1996, 34: 533-534.PubMedGoogle Scholar
  36. Wejse C, Olesen R, Rabna P, Kaestel P, Gustafson P, Aaby P, Andersen PL, Glerup H, Sodemann M: Serum 25-hydroxyvitamin D in a West African population of tuberculosis patients and unmatched healthy controls. A J Clin Nut. 2007, 86: 1376-1383.Google Scholar
  37. Tostmann A, Wielders JP, Kibiki GS, Verhoef H, Boeree MJ, van der Ven AJ: Serum 25-hydroxy-vitamin D3 concentrations increase during tuberculosis treatment in Tanzania. Int J Tuberc Lung Dis. 2010, 14: 1147-1152.PubMedGoogle Scholar
  38. Nielsen NO, Skifte T, Andersson M, Wohlfahrt J, Søborg B, Koch A, Melbye M, Ladefoged K: Both high and low serum vitamin D concentrations are associated with tuberculosis: a case–control study in Greenland. Br J Nut. 2010, 104: 1487-1491. 10.1017/S0007114510002333.View ArticleGoogle Scholar
  39. Banda R, Mhemedi B, Allain TJ: Prevalence of vitamin D deficiency in adult tuberculosis patients at a central hospital in Malawi. Int J Tuberc Lung Dis. 2011, 15: 408-410.PubMedGoogle Scholar
  40. Nansera D, Graziano FM, Friedman DJ, Bobbs MK, Jones AN, Hansen KE: Vitamin D and calcium levels in Ugandan adults with human immunodeficiency virus and tuberculosis. Int J Tuberc Lung Dis. 2011, 15: 1522-1527. 10.5588/ijtld.10.0701.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Gray K, Wood N, Gunasekera H, Sheikh M, Hazelton B, Barzi F, Isaacs D: Vitamin d and tuberculosis status in refugee children. Pediatr Infect Dis J. 2012, 31: 521-523. 10.1097/INF.0b013e3182456c55.View ArticlePubMedGoogle Scholar
  42. Williams B, Williams AJ, Anderson ST: Vitamin D deficiency and insufficiency in children with tuberculosis. Pediatr Infect Dis J. 2008, 27: 941-942. 10.1097/INF.0b013e31817525df.View ArticlePubMedGoogle Scholar
  43. Morcos MM, Gabr AA, Samuel S, Kamel M, el Baz M, el Beshry M, Michail RR: Vitamin D administration to tuberculous children and its value. Boll Chim Farm. 1998, 137: 157-164.PubMedGoogle Scholar
  44. Ralph AP, Lucas RM, Norval M: Vitamin D and solar ultraviolet radiation in the risk and treatment of tuberculosis. Lancet Infect Dis. 2013, 13: 77-88. 10.1016/S1473-3099(12)70275-X.View ArticlePubMedGoogle Scholar

Copyright

© Venturini et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement

BMC Infectious Diseases

ISSN: 1471-2334

Contact us